Storm Therapeutics, AlidaBio Team Up to Advance RNA-Targeting Cancer Therapy Development

Storm Therapeutics, AlidaBio Team Up to Advance RNA-Targeting Cancer Therapy Development

STORM Therapeutics has entered a strategic collaboration with AlidaBio to accelerate development of RNA-targeting cancer therapies by applying advanced sequencing technologies to analyse m6A RNA modifications in clinical samples from patients treated with STORM’s METTL3 inhibitor, STC-15.

Expanding Clinical Insights with Epitranscriptomic Profiling

Under the agreement, STORM will leverage AlidaBio’s EpiPlex® and EpiScout® next-generation sequencing platforms to detect and quantify transcript-specific N6-methyladenosine (m6A) modifications triggered by METTL3 inhibition. This initiative aims to correlate these molecular changes with clinical responses in Phase 1/2 studies of STC-15, potentially uncovering biomarkers to inform patient stratification.

Pioneering Precision Oncology Through Biomarker Strategies

The partnership reflects a broader push in oncology to integrate epitranscriptomic data into drug development, enhancing understanding of post-transcriptional regulation and enabling more precise therapeutic strategies. By identifying baseline m6A features linked to treatment sensitivity, the collaboration could refine patient selection and enrich future clinical trial designs.